IDP-023

The NK cell therapy market is experiencing robust growth driven by increasing interest in immuno-oncology and advancements in cell engineering technologies, with significant expansion expected through 2034.

Indapta Therapeutics has secured $22.5 million in funding to accelerate clinical trials of its allogeneic Natural Killer (NK) cell therapy, IDP-023.

Indapta Therapeutics and Sanofi are collaborating to assess IDP-023, an allogeneic g-NK cell therapy, combined with Sarclisa (isatuximab) for relapsed/refractory multiple myeloma.

The NK cell therapy field is experiencing significant growth, driven by its potential to address unmet needs in cancer treatment with safer, more targeted options.

Indapta Therapeutics' IDP-023 demonstrated preliminary clinical activity in relapsed/refractory multiple myeloma patients, even at the lowest dose without a targeting antibody.